Consensus and Position Papers on Cardiovascular Pharmacotherapy

ESC Working Group on Cardiovascular Pharmacotherapy

Date

Title

• Date: 2024
  Title: Update on antithrombotic therapy and body mass. A Clinical consensus Statement of the ESC Working Group on Cardiovascular Pharma
• Date: 2024
  Title: Management of cardiac emergencies in women
• Date: 2023
  Title: Acute LDL-C reduction post ACS: strike early and strike strong: from evidence to clinical practice. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Association of Preventive Cardiology (EAPC) and the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
• Date: 2022
  Title: Sex differences in arterial hypertension
• Date: 2022
  Title: Sex differences in arterial hypertension: A scientific statement from the ESC Council on Hypertension, the European Association of Preventive Cardiology, Association of Cardiovascular Nursing and Allied Professions, the ESC Council for Cardiology Practice, and the ESC Working Group on Cardiovascular Pharmacotherapy
• Date: 2022
  Title: Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
• Date: 2021
  Title: Challenges in Cardiovascular Pharmacogenomics Implementation: A viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
• Date: 2021
  Title: Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy
• Date: 2021
  Title: Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
• Date: 2021
  Title: The Role of Pharmacogenomics in Contemporary Cardiovascular Therapy: A position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
• Date: 2020
  Title: Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension Renata Cífková, Mark R Johnson, Thomas Kahan, Jana Brguljan, Bryan Williams ... European Heart Journal - Cardiovascular Pharmacotherapy, Volume 6, Issue 6, November 2020, Pages 384–393
• Date: 2020
  Title: An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: Barriers to be overcome
• Date: 2019
  Title: Lipid management in rheumatoid arthritis: a position paper by the Cardiovascular Pharmacotherapy Working Group of European Society of Cardiology.
• Date: 2018
  Title: Management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors
• Date: 2018
  Title: Antiarrhythmic drugs–clinical use and clinical decision making
• Date: 2017
  Title: Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
• Date: 2016
  Title: Myocardial infarction with non-obstructive coronary arteries
• Date: 2016
  Title: Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs
• Date: 2015
  Title: Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management
• Date: 2015
  Title: Gender differences in the effect of cardiovascular drugs
• Date: 2013
  Title: Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy
• Date: 2013
  Title: The use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy